by Elena Iemma | Feb 3, 2021 | Thinking Out Loud -Blog
The in silico tools here at EpiVax have been extensively validated, both internally and externally. That said, we always get a warm fuzzy feeling when we see our tools highlighted in papers and at conferences! Proud parents, we can’t help it😊 Just such a moment...
by Elena Iemma | Jan 26, 2021 | Events, Featured, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...
by Annie De Groot | Nov 6, 2019 | Featured, News
Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
by Annie De Groot | Dec 3, 2013 | News
Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A Dreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new...
by Annie De Groot | Oct 24, 2013 | Thinking Out Loud -Blog
EpiVax has produced 4 new Vaccine related posters for the upcoming ISV Conference and ICoVax Pre-Conference in Sitges Spain. Explore the links below for a PDF version of each poster. More EpiVax posters are available for viewing and download HERE. FastVax: Making...
